Practical implication
MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Health Canada amended the Prescription Drug List to include donanemab, islatravir, and pegzilarginase, necessitating prescription status for both human and veterinary use. This change imposes specific safety monitoring and reporting obligations on Marketing Authorization Holders (MAHs) and restricts direct-to-consumer advertising.
What changed: Donanemab, islatravir, and pegzilarginase have been added to the Prescription Drug List and are now classified as prescription drugs in Canada.
Why it matters: The prescription classification triggers mandatory safety monitoring and reporting processes for MAHs and limits advertising practices, influencing compliance and market behavior.
Practical implication: MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
View original source
Published from the Firecrawl policy change extraction pipeline.
